Email this article Bioregulatory therapy for chronic abacterial prostatitis
- Authors: Kuzmin I.V.1, Slesarevskaya M.N.1, Al-Shukri S.K.1
-
Affiliations:
- Academician I.P. Pavlov First St. Petersburg State Medical University
- Issue: Vol 12, No 3 (2022)
- Pages: 191-202
- Section: Original articles
- URL: https://bakhtiniada.ru/uroved/article/view/111581
- DOI: https://doi.org/10.17816/uroved111581
- ID: 111581
Cite item
Open Access
Access granted
Subscription Access
Abstract
BACKGROUND: Chronic abacterial prostatitis/chronic pelvic pain syndrome (CAP/CPPS) is the most common form of chronic prostatitis.
AIM: The aim of the study was to evaluate the effectiveness and tolerability of complex therapy in patients with CAP/CPPS using the bioregulatory peptide drug Uroprost-D.
MATERIALS AND METHODS: The study included 47 men aged 23 to 54 years (mean 38.1 ± 7.2 years) with CAP/CPPS (category III according to the NYHA classification, 1995). Patients of the 1st group (n = 24) were prescribed alpha-blocker tamsulosin 0.4 mg for 30 days and rectal suppositories Uroprost-D one per day for 15 days. Patients of the 2nd group (n = 23) were also prescribed tamsulosin 0.4 mg per day for 30 days and rectal suppositories indomethacin 100 mg, one per day for 15 days. The dynamics of clinical parameters was assessed on the 15, 30 and 60th day from the start of the study.
RESULTS: By the 15th day of the study, there was a significant positive dynamics of symptoms in patients of both groups. By the 30th day of the study in patients of the 1st group the treatment effect persisted, while in patients of the 2nd group pain increased, which was expressed in an increase in the scores for the “Pain” domains and the total score of the NIH-CPSI questionnaire. This trend is even more pronounced by the 60th day of observation, when a significant difference was found both in the total score of the NIH-CPSI questionnaire and separately in the domains “Pain”, “Dysuria” and “Quality of life”. During the study, there were no statistically significant changes in the maximum urine flow rate, prostate volume and residual urine volume. Tolerability of treatment was satisfactory, the frequency of negative manifestations was slightly higher in patients of the 2nd group.
CONCLUSIONS: The use of the bioregulatory peptide drug Uroprost-D in the complex therapy of patients with CAP was accompanied by a decrease in the severity of pain syndrome and dysuria. The appointment of Uroprost-D seems to be a pathogenetically justified alternative to the use of NSAIDs in this category of patients.
Full Text
##article.viewOnOriginalSite##About the authors
Igor V. Kuzmin
Academician I.P. Pavlov First St. Petersburg State Medical University
Email: kuzminigor@mail.ru
ORCID iD: 0000-0002-7724-7832
SPIN-code: 2684-4070
Scopus Author ID: 56878681300
https://www.ooorou.ru/ru/users/kuzminigor-mail-ru.html
Dr. Sci. (Med.), Professor of the Department of Urology
Russian Federation, 6–8, L’va Tolstogo st., Saint Petersburg, 197022Margarita N. Slesarevskaya
Academician I.P. Pavlov First St. Petersburg State Medical University
Email: mns-1971@yandex.ru
ORCID iD: 0000-0002-4911-6018
SPIN-code: 9602-7775
Scopus Author ID: 57196117211
https://www.1spbgmu.ru/ru/universitet/strustura/kafedry/106-glavnaya/3905-slesarevskaya-margarita-nikolaevna
Cand. Sci. (Med.), Senior Research Associate, Research Center of Urology of the Research Institute of Surgery and Emergency Medicine
Russian Federation, 6–8, L’va Tolstogo st., Saint Petersburg, 197022Salman Kh. Al-Shukri
Academician I.P. Pavlov First St. Petersburg State Medical University
Author for correspondence.
Email: alshukri@mail.ru
ORCID iD: 0000-0002-4857-0542
SPIN-code: 2041-8837
Scopus Author ID: 6506423220
Dr. Sci. (Med.), Professor, Head of the Department of Urology
Russian Federation, 6–8, L’va Tolstogo st., Saint Petersburg, 197022References
- Krieger JN, Lee SW, Jeon J, et al. Epidemiology of prostatitis. Int J Antimicrob Agents. 2008;31Suppl 1(Suppl 1): S85–S90. doi: 10.1016/j.ijantimicag.2007.08.028
- Krieger JN, Nyberg L Jr, Nickel JC. NIH consensus definition and classification of prostatitis. JAMA. 1999;282(3):236–237. doi: 10.1001/jama.282.3.236
- Al-Shukri SK, Gorbachev AG, Borovets SYu, et al. Pathogenesis and prophylaxis of chronic prostatitis (clinical and experimental study). Urologicheskie vedomosti. 2012;2(2):15–19. (In Russ.) doi: 10.17816/uroved2215-19
- Tsukanov AYu, Lyashev RV. Disorders of venous blood flow as a cause of chronic abacterial prostatitis (chronic pelvic pain syndrome). Urologiia. 2014;(4):37–42. (In Russ.)
- Tsukanov AYu, Rudchenko NV, Kuzovkin AN, et al. Prostate state under varicosis of the pelvis (experimental study). Urology Reports (St. Petersburg.) 2021;11(2):97–104. (In Russ.) doi: 10.17816/uroved64917
- Anothaisintawee T, Attia J, Nickel JC, et al. Management of chronic prostatitis/chronic pelvic pain syndrome: a systematic review and network meta-analysis. JAMA. 2011;305(1):78–86. doi: 10.1001/jama.2010.1913
- Bozhedomov VA. Modern opportunities for the treatment of chronic prostatitis. Andrology and Genital Surgery. 2016;17(3):10–22. (In Russ.) doi: 10.17650/2070-9781-2016-17-3-10-22
- Nesina IА, Kulishova ТV, Poteryaeva ЕL, Smirnova ЕL. Drug-free rehabilitation programs for patients with abacterial prostatitis. Journal of Siberian Medical Sciences. 2020;(2):67–76 (In Russ.) doi: 10.31549/2542-1174-2020-2-67-76
- Tyuzikov IA, Grekov EA. Chronic prostatitis/chronic pelvic pain syndrome: current trends and prospects for treatment from the standpoint of evidence-based medicine. Experimental and Clinical Urology. 2022;15(1):90–101. (In Russ.) doi: 10.29188/2222-8543-2022-15-1-90-100
- Neymark AI, Neymark BA, Borisenko DV, Maksimova SS. Complex conservative therapy of chronic abacterial prostatitis. Urology Reports (St. Petersburg). 2021;11(4):315–324. (In Russ.) doi: 10.17816/uroved71567
- Engeler D, Baranowski AP, Berghmans B, et al. EAU Guideline on Chronic Pelvic Pain. EAU Guidelines Office, Arnhem, Netherlands. 2022. Available from: https://uroweb.org/guidelines/chronic-pelvic-pain
- Doiron RC, Shoskes DA, Nickel JC. Male CP/CPPS: where do we stand? World J Urol. 2019;37(6):1015–1022. doi: 10.1007/s00345-019-02718-6
- Nickel JC. Is chronic prostatitis/chronic pelvic pain syndrome an infectious disease of the prostate? Investig Clin Urol. 2017;58(3): 149–151. doi: 10.4111/icu.2017.58.3.149
- Kuznik BI, Morozov VG, Khavinson VKh. Tsitomediny i ikh rol’ v regulyatsii fiziologicheskikh funktsii. Uspekhi Sovremennoi Biologii. 1995;115(3):353–367. (In Russ.)
- Khavinson VKh, Morozov VG, Kuznik BI, et al. Vliyanie polipeptidov predstatel’noi zhelezy na sistemu gemostaza. Farmakologiya i Toksikologiya. 1985;48(5):69–71. (In Russ.)
- Yushkov VV, Khavinson VKh. Vyyavlenie i analiz protivovospalitel’noi aktivnosti immunomodulyatorov. Patologicheskaya Fiziologiya i Eksperimental’naya Terapiya. 1993;37(2):11–13. (In Russ.)
- Barabanova VV, Gorbachev AG, Parastaeva MM, Khavinson VKh. The effect of prostatic peptides on the contractile activity of smooth-muscle cells from the bladder. Russian Journal оf Physiology. 1993;79(2):90–96. (In Russ.)
- Tkachuk VN, Gorbachev AG, Khavinson VKh. Primenenie prostatilena pri lechenii bol’nykh khronicheskim prostatitom. Urologiya i Nefrologiya. 1991;(6):40–43. (In Russ.)
- Al-Shukri SK, Gorbachev AG, Kuzmin IV. Bioreguliruyushchaya terapiya bol’nykh khronicheskim pielonefritom. Urologiya i Nefrologiya. 1997;(4):6–8. (In Russ.)
- Al’-Shukri SKh, Kuz’min IV, Lukina EE. Uroprost peptide complex in treatment of patients with voiding disturbances. Experimental & Clinical Urology. 2010;(3):80–84. (In Russ.)
- Kuz’min IV. Vitaprost forte in the treatment of patients with benign prostatic hyperplasia: pathogenetic basics and clinical results. Urologiia. 2019;(4):141–147. (In Russ.) doi: 10.18565/urology.2019.4.141-147
- Kuzmenko AV, Vinnik YuYu, KuzmenkoVV, Gyaurgiev TA. The use of bioregulatory peptides in the treatment of men with benign prostatic hyperplasia and chronic prostatitis. Urologiia. 2021;3:70–74 doi: 10.18565/urology.2021.3.70-74
- Kuzmin IV, Borovets SYu, Gorbachev AG, Al-Shukri SK. Prostatic bioregulatory polypeptide prostatilen: pharmacological properties and 30-year experience of clinical application in urology. Urology Reports (St. Petersburg). 2020;10(3):243–258. (In Russ.) doi: 10.17816/uroved42472
- Al’-Shukri SX, Gorbachev AG, Borovets SYu, et al. Prostatilen treatment of prostatic adenoma. Urologiia. 2006;(6):22–25. (In Russ.)
- Dyadyk AI, Kugler TE. Side effects of non-steroidal anti-inflammatory drugs. Consilium Medicum. 2017;19(12):94–99. (In Russ.) doi: 10.26442/2075-1753_19.12.94-99
- Karateev AE, Nasonov EL, Ivashkin VT, et al. Rational use of nonsteroidal anti-inflammatory drugs. Clinical guidelines. Rheumatology Science and Practice. 2018;56(Suppl. 1):1–29. (In Russ.) doi: 10.14412/1995-4484-2018-1-29
- Fedoreeva LI, Kireev II, Havinson VH, Vanjushin B. Penetration of short fluorescence-labeled peptides into the nucleus in HELA cells and in vitro specific interaction of the peptides with deoxyribooligonucleotides and DNA. Biochemistry (Moscow). 2011;76(11):1505–1516. (In Russ.) DOI: 0.1134/S0006297911110022
Supplementary files
